Ascletis Pharma Inc. (1672.HK) HKSE
Currency In HKD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In HKD
Sector
Healthcare
Industry
Biotechnology
Employees
202
First IPO Date
August 01, 2018
| Name | Title | Pay | Year Born |
| Jinzi Wu | Founder, Chairman & Chief Executive Officer | 117.71M | 1964 |
| Hejingdao Wu | Senior Vice President of Operations & Executive Director | 7.16M | 1974 |
| Ming Fai Chung | Company Secretary | 0 | 1979 |
| George Zhengzhi Hill | Senior Consultant & Chief Medical Advisor | 0 | 1951 |
| Kristjan Sigurdur Gudmundsson | Senior Consultant & Head of Discovery | 0 | 1968 |
| John Gargiulo | Chief Business Officer | 0 | 1960 |
Ascletis Pharma Inc., a biotechnology company, engages in the research and development, manufacture, marketing, and sale of pharmaceutical products in Mainland China. The company’s commercial products include Ritonavir tablet; and ASCLEVIR and GANOVO for use in the treatment of Hepatitis C virus. It is also developing ASC22 for treating CHB and HIV functional cure; ASC10 for treating respiratory syncytia virus; ASC10 and ASC11 to treat COVID-19; ASC40, ASC41, and ASC43F FDC for non-alcoholic steatohepatitis; and ASC42 for the treatment of primary biliary cholangitis. In addition, the company is developing ASC40 to treat recurrent glioblastoma; ASC61 for advanced solid tumors; and ASC40, an oral small molecule for the treatment of acne. Ascletis Pharma Inc. was founded in 2013 and is based in Hangzhou, the People’s Republic of China.